Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free GNCAQ Stock Alerts

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo
Compare

GNCAQ vs. SCPS, SMFL, NAVB, PXMD, and GNCA

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Scopus BioPharma (SCPS), Smart for Life (SMFL), Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Genocea Biosciences N/A N/A N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Genocea Biosciences Neutral

Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Genocea Biosciences beats Scopus BioPharma on 1 of the 1 factors compared between the two stocks.

How does Genocea Biosciences compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A N/A N/A

Smart for Life has a beta of 15.1, indicating that its stock price is 1,410% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genocea Biosciences has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Summary

Smart for Life beats Genocea Biosciences on 5 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Genocea Biosciences has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to PaxMedica?

Genocea Biosciences (NASDAQ:GNCAQ) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Genocea Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
PaxMedica Neutral

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

4.9% of PaxMedica shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genocea Biosciences has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Genocea Biosciences Neutral

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Genocea Biosciences N/A N/A N/A

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

Summary

Genocea Biosciences beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCAQ vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.27273.2925.25
Price / SalesN/A754.88623.6797.64
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.926.14
Net IncomeN/A$2.82B$3.47B$349.01M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
SMFL
Smart for Life
N/A$0.00
+566.7%		N/A-92.6%$14K$11.11MN/A110
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
PXMD
PaxMedica
N/A$0.00
+40.0%		N/AN/A$8KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel